Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein

Abstract Severe COVID-19 is characterized by thrombo-inflammatory processes within the lung microvasculature. In pursuit of effective treatments, clinical studies explored mesenchymal stromal cells (MSCs) as a promising approach due to their anti-inflammatory, immunomodulatory, and regenerative prop...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Pezzotta, Alessandra Bovio, Barbara Imberti, Monica Locatelli, Daniela Corna, Domenico Cerullo, Sara Gastoldi, Ariela Benigni, Giuseppe Remuzzi, Marina Morigi, Luca Perico
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Stem Cell Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13287-025-04472-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849403161591152640
author Anna Pezzotta
Alessandra Bovio
Barbara Imberti
Monica Locatelli
Daniela Corna
Domenico Cerullo
Sara Gastoldi
Ariela Benigni
Giuseppe Remuzzi
Marina Morigi
Luca Perico
author_facet Anna Pezzotta
Alessandra Bovio
Barbara Imberti
Monica Locatelli
Daniela Corna
Domenico Cerullo
Sara Gastoldi
Ariela Benigni
Giuseppe Remuzzi
Marina Morigi
Luca Perico
author_sort Anna Pezzotta
collection DOAJ
description Abstract Severe COVID-19 is characterized by thrombo-inflammatory processes within the lung microvasculature. In pursuit of effective treatments, clinical studies explored mesenchymal stromal cells (MSCs) as a promising approach due to their anti-inflammatory, immunomodulatory, and regenerative properties, through their paracrine action. Here, we tested the conditioned medium (CM) derived from human umbilical cord (UC)-MSCs in acute lung injury induced by the spike protein subunit 1 (S1) in ACE2-humanized male mice. Injection of CM significantly limited S1-induced lung injury, edema, and fibrosis. This was associated with reduced vascular dysfunction, in terms of restored thrombomodulin levels and decreased von Willebrand (vWF) expression. By preserving endothelial glycocalyx, CM reduced complement C3 accumulation, favoring factor H binding on the lung microvasculature. Reduced oxidative stress, nuclear NF-κB p65 accumulation, and inflammatory cell infiltration were also observed in response to CM in S1-injected mice. In vitro, CM counteracted thrombo-inflammation by preserving thrombomodulin, as well as limiting vWF expression, due to endothelial glycocalyx recovery. CM reduced nuclear translocation of NF-κB p65 and its downstream targets, ICAM-1 and P-selectin, translating in decreased C3 deposits, platelet aggregation, and leukocyte adhesion on S1-challenged endothelial cells. Collectively, these data indicate that UC-MSC-derived secretome represents a promising therapy in COVID-19 due to its potent anti-thrombotic and anti-inflammatory effects on lung microcirculation.
format Article
id doaj-art-ad7fa06c07eb4a7eaccfcc634d0584e7
institution Kabale University
issn 1757-6512
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Stem Cell Research & Therapy
spelling doaj-art-ad7fa06c07eb4a7eaccfcc634d0584e72025-08-20T03:37:20ZengBMCStem Cell Research & Therapy1757-65122025-07-0116112010.1186/s13287-025-04472-6Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike proteinAnna Pezzotta0Alessandra Bovio1Barbara Imberti2Monica Locatelli3Daniela Corna4Domenico Cerullo5Sara Gastoldi6Ariela Benigni7Giuseppe Remuzzi8Marina Morigi9Luca Perico10Department of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCSAbstract Severe COVID-19 is characterized by thrombo-inflammatory processes within the lung microvasculature. In pursuit of effective treatments, clinical studies explored mesenchymal stromal cells (MSCs) as a promising approach due to their anti-inflammatory, immunomodulatory, and regenerative properties, through their paracrine action. Here, we tested the conditioned medium (CM) derived from human umbilical cord (UC)-MSCs in acute lung injury induced by the spike protein subunit 1 (S1) in ACE2-humanized male mice. Injection of CM significantly limited S1-induced lung injury, edema, and fibrosis. This was associated with reduced vascular dysfunction, in terms of restored thrombomodulin levels and decreased von Willebrand (vWF) expression. By preserving endothelial glycocalyx, CM reduced complement C3 accumulation, favoring factor H binding on the lung microvasculature. Reduced oxidative stress, nuclear NF-κB p65 accumulation, and inflammatory cell infiltration were also observed in response to CM in S1-injected mice. In vitro, CM counteracted thrombo-inflammation by preserving thrombomodulin, as well as limiting vWF expression, due to endothelial glycocalyx recovery. CM reduced nuclear translocation of NF-κB p65 and its downstream targets, ICAM-1 and P-selectin, translating in decreased C3 deposits, platelet aggregation, and leukocyte adhesion on S1-challenged endothelial cells. Collectively, these data indicate that UC-MSC-derived secretome represents a promising therapy in COVID-19 due to its potent anti-thrombotic and anti-inflammatory effects on lung microcirculation.https://doi.org/10.1186/s13287-025-04472-6COVID-19Spike protein 1ComplementEndothelial dysfunctionGlycocalyxThrombo-inflammation
spellingShingle Anna Pezzotta
Alessandra Bovio
Barbara Imberti
Monica Locatelli
Daniela Corna
Domenico Cerullo
Sara Gastoldi
Ariela Benigni
Giuseppe Remuzzi
Marina Morigi
Luca Perico
Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein
Stem Cell Research & Therapy
COVID-19
Spike protein 1
Complement
Endothelial dysfunction
Glycocalyx
Thrombo-inflammation
title Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein
title_full Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein
title_fullStr Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein
title_full_unstemmed Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein
title_short Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein
title_sort mesenchymal stromal cell secretome reduces lung injury and thrombo inflammation induced by sars cov 2 spike protein
topic COVID-19
Spike protein 1
Complement
Endothelial dysfunction
Glycocalyx
Thrombo-inflammation
url https://doi.org/10.1186/s13287-025-04472-6
work_keys_str_mv AT annapezzotta mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT alessandrabovio mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT barbaraimberti mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT monicalocatelli mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT danielacorna mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT domenicocerullo mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT saragastoldi mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT arielabenigni mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT giusepperemuzzi mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT marinamorigi mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein
AT lucaperico mesenchymalstromalcellsecretomereduceslunginjuryandthromboinflammationinducedbysarscov2spikeprotein